Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1988 Feb;26(1):11–17. doi: 10.1007/BF00199841

Augmentative effect of Nocardia rubra cell-wall skeleton (N-CWS) on lymphokine-activated killer (LAK) cell induction

Soichiro Yokota 1, Takuma Shirasaka 1, Hideki Nishikawa 2, Shigeto Hosoe 1, Toshiyuki Ikeda 1, Kiyoshi Komuta 1, Ichiro Kawase 1, Tomiya Masuno 1, Takeshi Ogura 3, Susumu Kishimoto 1
PMCID: PMC11038287  PMID: 3257899

Abstract

The present study elucidated that N-CWS augments the cytolytic activity against 3LL tumor cells of LAK cells from N-CWS-immunized mice administered i.p. with rIL-2. This augmentative effect of N-CWS was not seen when the LAK cells were prepared from normal mice. The cytolytic activity was predominantly expressed in the NAPC prepared from the site of injection of rIL-2, and repeated administrations of rIL-2 were required to induce and maintain this potent cytolytic activity in vivo. Serological analysis revealed that the LAK cells were positive for Thy 1.2 and asialo GM1 antigens and that they were not classical CTL or NK cells. The administration of rIL-2 statistically prolonged the MST of mice bearing LAK-sensitive 3LL cells but not the MST of mice bearing LAK-resistant EL-4 leukemia. Furthermore, combination therapy with N-CWS and rIL-2 prolonged the MST of the mice more than the therapy with rIL-2 alone. These results suggest that LAK cells potentiated with N-CWS would be useful for immunotherapy of malignant neoplasms.

Keywords: Tumor Cell, Leukemia, Malignant Neoplasm, Normal Mouse, Cell Induction

Footnotes

Abbreviations used: N-CWS, Nocardia rubra cell-wall skeleton; rIL-2, recombinant interleukin 2; LAK, lymphokine-activated killer; RPMI 1640, Roswell Park Memorial Institute 1640; FCS, fetal calf serum; TCM, tumor culture medium; PC, peritoneal cells; NAPC, nonadherent PC; APC adherent PC; MST, mean survival time; NK, natural killer; E:T ratios, effector to target ratios; Poly I:C, polyinosinic-polycytidylic acid; CTL, cytotoxic T lymphocytes; RLNC, regional lymphnode cells

References

  • 1.Azuma I, Taniyama T, Yamawaki M, Sugimura K, Yamamura Y. Adjuvant and antitumor activities of Nocardia cell-wall skeletons. Gann. 1976;67:733. [PubMed] [Google Scholar]
  • 2.Chang AE, Hyatt CL, Rosenberg SA. Systemic administration of recombinant human interleukin-2 in mice. J Biol Response Mod. 1984;3:561. [PubMed] [Google Scholar]
  • 3.Cheever MA, Thompson JA, Kern DE, Greenberg PH. Interleukin 2 (IL-2) administered in vivo: Influence of IL-2 route and timing on T cell growth. J Immunol. 1985;134:3895. [PubMed] [Google Scholar]
  • 4.Devos R, Plaetinck G, Fiers W. Induction of cytolytic cells by pure recombinant human interleukin 2. Eur J Immunol. 1984;14:1057. doi: 10.1002/eji.1830141118. [DOI] [PubMed] [Google Scholar]
  • 5.Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. J Immunol. 1983;130:2203. [PubMed] [Google Scholar]
  • 6.Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Hayashi S, Masuno T, Hosoe S, Kawase I, Sakatani M, Ogura T, Kisimoto S, Yamamura Y. Augmented production of colony stimulating factor in C3H/HeN mice immunized with Nocardia rubra cell wall skeleton. Infect Immun. 1986;52:128. doi: 10.1128/iai.52.1.128-133.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Hefeneider SH, Conlon PJ, Henney CS, Gillis S. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol. 1983;130:222. [PubMed] [Google Scholar]
  • 9.Hinuma S, Naruo K, Shiho O, Tsukamoto K. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2. Immunology. 1986;59:251. [PMC free article] [PubMed] [Google Scholar]
  • 10.Ito M, Iizuka H, Masuno T, Yasunami R, Ogura T, Yamamura Y, Azuma I. Killing of tumor cells in vitro by macrophages from mice given injections of squalene-treated cell wall skeleton of Nocardia rubra . Cancer Res. 1981;41:2925. [PubMed] [Google Scholar]
  • 11.Izumi S, Ueda H, Okuhara M, Aoki H, Yamamura Y. Effect of Nocardia rubra cell wall skeleton on murine interferon production in vitro. Cancer Res. 1986;46:1960. [PubMed] [Google Scholar]
  • 12.Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res. 1986;46:2101. [PubMed] [Google Scholar]
  • 13.Kawase I, Uemiya M, Yoshimoto T, Ogura T, Hirao F, Yamamura Y. Effect of Nocardia rubra cell wall skeleton on T-cell-mediated cytotoxicity in mice bearing syngeneic sarcoma. Cancer Res. 1981;41:660. [PubMed] [Google Scholar]
  • 14.Masuno T, Hayashi S, Ito M, Ikeda T, Ogura T, Kishimoto S, Yamamura Y. Mechanism(s) of in vitro macrophage activation with Nocardia rubra cell wall skeleton: the effects on macrophage activating factor production by lymphocytes. Cancer Immunol Immunother. 1986;22:132. doi: 10.1007/BF00199127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Nakamura H, Masuoka T, Ohno R, Yamada K, Ogawa N. A randomized control study on immunotherapy for acute myelogenous leukemia with Nocardia rubra cell wall skeleton and irradiated allogenic leukemia cells. Acta Haematol Jpn. 1983;46:1087. [PubMed] [Google Scholar]
  • 16.Nishimura T, Togashi Y, Goto M, Yugi H, Uchiyama Y, Hashimoto Y. Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2. Cancer Immunol Immunother. 1986;21:12. doi: 10.1007/BF00199371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Papa MZ, Mule JJ, Rosenberg SA. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histological types. Cancer Res. 1986;46:4973. [PubMed] [Google Scholar]
  • 18.Rayner AA, Grimm EA, Lotze Mt, Chu EW, Rosenberg SA. Lymphokine-Activated Killer (LAK) cells: analysis of factors relevant to the immunotherapy of human cancer. Cancer. 1985;55:1327. doi: 10.1002/1097-0142(19850315)55:6<1327::aid-cncr2820550628>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  • 19.Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl J Med. 1985;313:1485. doi: 10.1056/NEJM198512053132327. [DOI] [PubMed] [Google Scholar]
  • 20.Rosenber SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastasis and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985;161:1169. doi: 10.1084/jem.161.5.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res. 1984;44:1946. [PubMed] [Google Scholar]
  • 22.Sato H, Ochiai T, Hayashi R, Watanabe K, Asano T, Isono K, Tanaka T. Result of randomized clinical trial of Nocardia rubra-CWS on postoperable gastric cancer patients. J Jpn Surg Soc. 1982;83:635. [Google Scholar]
  • 23.Sayers T, Rossiter H, Chung J, Hren A, Armerding D. In vivo activation of murine natural killer cell functions by human recombinant DNA interleukin 2. Immunobiology. 1985;169:303. doi: 10.1016/S0171-2985(85)80042-5. [DOI] [PubMed] [Google Scholar]
  • 24.Ting CC, Yang SS. Effect of interleukin 2 on cytotoxic effectors. 1. Short-term culture of the cytotoxic effectors and the in vivo anti-tumor activity of the cultured effectors isolated from tumor site. Int J Cancer. 1982;30:625. doi: 10.1002/ijc.2910300513. [DOI] [PubMed] [Google Scholar]
  • 25.Ting CC, Yang SS, Hargrove ME. Lymphokine-induced cytotoxicity: characterization of effectors, precursors, and regulatory ancillary cells. Cancer Res. 1986;46:513. [PubMed] [Google Scholar]
  • 26.Thompson JA, Peace DJ, Klarnet JP, Kern DE, Greenberg PD, Cheever MA. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2. J Immunol. 1986;137:3675. [PubMed] [Google Scholar]
  • 27.Yamaguchi T, Tchimaru M, Kohno F, Takatsuki K, Kishimoto S, Araki K, Tomosue H, Takada M, Matsumoto M, Yuki K, Kishioka K, Hashimoto S, Ogawa N. Adjuvant activity of Nocardia cell-wall skeleton on maintenance chemotherapy of acute nonlymphatic leukemia. Acute Haematol Jpn. 1983;46:1093. [PubMed] [Google Scholar]
  • 28.Yamamura Y, Ogura Y, Sakatani M, Hirao F, Kishimoto S, Fukuoka M, Takada M, Kawahara M, Furuse K, Kuwahara O, Ikegami H, Ogawa N. Randomized controlled study of adjuvant immunotherapy with Nocardia rubra cell wall skeleton for inoperable lung cancer. Cancer Res. 1983;43:5575. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES